References
- Wang Y, Nakajima A, Hosokawa K, et al. Cytotoxic prodigiosin family pigments from Pseudoalteromonas sp. 1020R isolated from the Pacific coast of Japan. Biosci Biotechnol Biochem 2012;76:1229–32
- Williamson NR, Fineran PC, Gristwood T, et al. Anticancer and immunosuppressive properties of bacterial prodiginines. Future Microbiol 2007;2:605–18
- Montaner B, Pérez-Tomás R. The prodigiosins: a new family of anticancer drugs. Curr Cancer Drug Target 2003;3:57–65
- Pandey R, Chander R, Sainis KB. Prodigiosins as anti-cancer agents: living up to their name. Curr Pharm Des 2009;15:732–41
- Fürstner A, Reinecke K, Prinz H, Waldmann H. The core structures of roseophilin and the prodigiosin alkaloids define a new class of protein tyrosine phosphatase inhibitors. ChemBioChem 2004;5:1575–9
- Toomik R, Ek P. A potent and highly selective peptide substrate for protein kinase C assay. Biochem J 1997;322:455–60
- Ravi R, Jain AJ, Schulick RD, et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 Ligand/TRAIL. Cancer Res 2004;64:9105–14
- Castillo-Ávila W, Abal M, Robine S, Pérez-Tomás R. Non-apoptotic concentrations of prodigiosin (H+/Cl− symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci 2005;78:121–7
- Montaner B, Navarro S, Piqué M, et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br J Pharmacol 2000;131:585–93
- Soto-Cerrato V, Viñals F, Lambert JR, Pérez-Tomás R. The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochem Pharmacol 2007;74:1340–9
- Ju JF, Banerjee D, Lenz HJ, et al. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res 1998;4:1315–22
- Feinstein E, Gale RP, Reed J, Canaani E. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 1992;7:1853–7
- Yu JL, Rak JW, Coomber BL,et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526–8
- Ramoneda BM, Pérez-Tomás R. Activation of protein kinase C for protection of cells against apoptosis induced by the immunosuppressor prodigiosin. Biochem Pharmacol 2002;63:463–9
- Zhang S, Zhang Z-Y. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today 2007;12:373–81
- Combs AP. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 2010;53:2333–44
- Stuible M, Doody KM, Tremblay ML. PTP1B and TC-PTP: regulators of transformation and tumorigenesis. Cancer Metastasis Rev 2008;27:215–30